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Abstract
Background: Whereas brain-derived neurotrophic factor (BDNF) levels are measured in the brain in animal models of stroke,
neurotrophin levels in stroke patients are measured in plasma or serum samples. The present study was designed to
investigate the meaning of circulating BDNF levels in stroke patients.
Methods and Results: Unilateral ischemic stroke was induced in rats by the injection of various numbers of microspheres
into the carotid circulation in order to mimic the different degrees of stroke severity observed in stroke patients. Blood was
serially collected from the jugular vein before and after (4 h, 24 h and 8 d) embolization and the whole brains were
collected at 4, 24 h and 8 d post-embolization. Rats were then selected from their degree of embolization, so that the
distribution of stroke severity in the rats at the different time points was large but similar. Using ELISA tests, BDNF levels
were measured in plasma, serum and brain of selected rats. Whereas plasma and serum BDNF levels were not changed by
stroke, stroke induced an increase in brain BDNF levels at 4 h and 24 h post-embolization, which was not correlated with
stroke severity. Individual plasma BDNF levels did not correlate with brain levels at any time point after stroke but a positive
correlation (r=0.67) was observed between individual plasma BDNF levels and stroke severity at 4 h post-embolization.
Conclusion: Circulating BDNF levels do not mirror brain BDNF levels after stroke, and severe stroke is associated with high
plasma BDNF in the very acute stage.
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Introduction
Brain-derived neurotrophic factor (BDNF), which is mainly
synthesized by neurons, is present in large amounts in the adult brain
where it plays a crucial role in plasticity and function [1]. Blood also
contains BDNF, which is at a higher concentration in serum than in
plasma since platelets release BDNF during the clotting process [2].
Indeed, platelets which cannot synthesize BDNF are rich in BDNF
because they are able to take up the BDNF present in plasma.
However, the cellular source of the BDNF present in plasma is not
known. BDNF may be secreted into the plasma by endothelial or
circulating immune cells [3–6]. From the evidence of parallel changes
in serum and cortical brain BDNF during postnatal development in
rats [7], the brain has been assumed to be an additional source of the
BDNF present in plasma. Nevertheless, recent studies have shown that
changes in regional brain BDNF levels are not associated with
respective changes in plasma or serum [8–10].
Brain BDNF has been extensively studied in animal models of
ischemic stroke. The studies consistently showed that brain BDNF
levels increased after stroke [11–13], suggesting that BDNF
promoted post-lesional plasticity [12,14,15]. A few studies have
focused on BDNF in stroke patients [16–19]. In these studies,
neurotrophin levels were measured in blood samples. In the
interpretation of circulating BDNF levels it was assumed that
BDNF levels increased in the brain of stroke patients as observed
in animals and that circulating BDNF levels mirrored brain BDNF
levels. However, BDNF levels have never been measured in post-
mortem brains of stroke patients. Moreover, an unresolved but
important question is whether circulating BDNF levels are
modified by stroke. Indeed, circulating BDNF levels before
hospital admission are unknown in patients, and there are no
studies on circulating BDNF levels in animal models of stroke.
In order to help the interpretation of circulating BDNF levels in
stroke patients, we measured BDNF levels in plasma, serum, and
brain before and up to 8 days after the induction of embolic stroke
in rats. This study, which is the first to document circulating
BDNF levels in an animal model of stroke, was designed to answer
the following questions: 1) does stroke induce changes in
circulating BDNF levels? 2) do circulating BDNF levels mirror
brain BDNF levels after stroke?
Materials and Methods
All experimental procedures were performed on laboratory
animals in accordance with institutional guidelines for the care and
use of laboratory animals and were approved by an official
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per cage at 21uC in an artificial 12-h light and 12-h dark cycle with
lights on at 7 am, and food and water ad libitum.
1) Induction of ischemic stroke
Multifocal infarction of the left hemisphere was induced in the
rats by injection into the left carotid circulation of 50 mm-
calibrated microspheres (carbonized microspheres, 3 M, Cergy-
Pontoise, France), a model that is routinely used in our laboratory
[13,20–24]. In order to mimic the different degrees of stroke
severity observed in patients, we chose this model that offers the
unique opportunity to modulate stroke severity voluntarily by
changing the number of injected microspheres, and that results in
increased BDNF content of both hemispheres, but with a greater
and more sustained increase in the lesioned than in the unlesioned
hemisphere [13]. Animal death induced by embolization is in
proportion with the number of injected microspheres and occurs
mainly overnight after embolization. Briefly, after anaesthesia with
chloral hydrate (400 mg/kg, i.p.) and definitive occlusion of the
external carotid artery in order to prevent embolization of
extracerebral tissue, a suspension of 2000, 3000 or 4000
microspheres in polyvinylpyrrolidone (20% in water) was injected
(0.3 ml for 25–30 s) into the left common carotid artery. Then, the
artery was definitively occluded. The embolized rats were assigned
into one of the three time groups (‘‘stroke 4 h’’, ‘‘stroke 24 h’’ and
‘‘stroke 8 d’’) according to the delay (4 h, 24h and 8 d) between
embolization and brain removal. Each group included rats
embolized with 2000, 3000 and 4000 microspheres.
2) Preparation of brain samples
The brains were collected after choral hydrate anaesthesia
followed by transcardial perfusion with saline in order to flush
blood out of the cerebral vasculature. The cerebellum, hypothal-
amus and mesencephale were discarded. The remaining hemi-
spheres were homogenized in 7 volumes with ice cold buffer
(pH 7.4) containing trizma base (100 mmol/L), NaCl (150 mmol/
L), EGTA (1 mmol/L), triton (1%) and 1% cocktail of protease
inhibitors. After centrifugation, tissue pellets were kept to assess the
degree of embolization and supernatants were stored at 280uC
until measurement of BDNF levels. When indicated, the
remaining hemispheres were dissected in order to measure BDNF
levels in the hippocampus, the thalamus, the striatum, and the
entire cortex that were homogenized as indicated above.
3) Preparation of blood samples
Blood was withdrawn (by direct venous puncture) from the
jugular vein, a vein that collects blood from the entire brain, before
and after (4 h, 24 h, 8 d) embolization in the same rats. Two, 3 or 4
samples (1 ml each) were serially collected according to the time
group of the stroke rats. The first and last samples were collected
under chloral anaesthesia just before embolization and just before
removal of the brain. Intermediate samples, if present, were
collected under short-term halothane anaesthesia in order to reduce
theoveralldurationofthe anaesthesia.Asthe circadianrhythmmay
influence circulating BDNF levels [25], blood samples were always
collected between 10 am and 2 pm. The blood was collected into
sampling tubes and centrifuged to obtain serum or heparin-
anticoagulated plasma. The plasma and serum were then divided
into aliquots and stored at 280uC until BDNF measurements.
4) Assessment of the degree of embolization
As it is technically not feasible to simultaneously measure in the
same rats the volume of infarcted tissue using histological method
and the BDNF content of the whole brain, stroke severity was
assessed from the degree of cerebral embolization. Indeed, we
previously reported a strong correlation between the degree of
cerebral embolization and clinically-pertinent markers of stroke
severity including brain depletion in the neuronal marker N-
acetyl-aspartate, vasogenic edema and acute neurological deficit
[20–22]. In order to quantify the degree of cerebral embolization,
the centrifugation pellets of brain tissue were dissolved in 5 ml of
20% KOH and centrifuged (500 g). The microspheres were then
re-suspended in 0.5 ml KOH, and counted in triplicate in 50 mlo f
the suspension by a person blinded to the experimental conditions.
A light microscope was used to count the microspheres.
5) BDNF measurement
BDNF levels were determined with a commercial sandwich
ELISA kit (ChemiKine
TM, Cat. No CYT306, MERCK MILLI-
PORE). For this kit, rabbit polyclonal antibodies that were coated
onto plates were generated against human BDNF and the
captured BDNF were detected using biotin conjugated mouse
monoclonal antibodies. BDNF antibodies do not cross with NGF,
NT 4/5 or NT3. BDNF furnished by the kit to make the standard
curve corresponds to the mature form of BDNF as revealed by an
immunoblot analysis (data not shown). The limit of sensitivity was
6 pg/mL. The experimental procedure was performed according
to the manufacturer’s instructions. Supernatants of brain homog-
enates and serum samples were diluted (1/10, v/v) in the
homogenization buffer (see above for its composition) and in
TRIS buffer (pH 7.4). The diluted samples (50 mL) were again
diluted (1/2, v/v) directly on the plate in a buffer provided by the
kit. In contrast, plasma samples were not diluted (100 mLo f
plasma into each well). All assays were performed in duplicate.
Brain BDNF levels were expressed as mg/g of fresh tissue and
circulating BDNF levels as ng/mL.
6) Statistical analysis
Data are expressed as mean 6 standard deviation (SD).
Statistical analysis was performed using non-parametric tests.
The Kruskall Wallis test followed by the Mann–Whitney test was
used to detect differences between groups of rats, and the
Friedman’s test followed by the Willcoxon’s test to detect
differences within a given group The Bonferroni’s procedure was
used to reduce the risk I error. The Spearman’s rank correlation
coefficient (rs) was calculated to examine the dependence between
two variables. Significance was set at p,0.05.
Results
Embolized rats (n=81) were divided into the following groups:
‘‘stroke 4 h’’ (n=15), ‘‘stroke 24 h’’ (n=26), ‘‘stroke 8 d’’ (n=20)
and ‘‘stroke 8 ds’’ (n=20). In the first three groups, blood samples
were treated in order to obtain plasma while in the last group
blood samples were treated in order to obtain serum. Serum and
plasma BDNF levels were collected in separate groups of rats in
order to avoid excessive blood withdrawal in a given rat. No
mortality was observed in group ‘‘stroke 4 h’’. In contrast,
mortality reached 54% (14/26) in group ‘‘stroke 24 h’’ (2 rats
died under halothane anaesthesia and 12 rats from embolization),
40% (8/20) in group ‘‘stroke 8 d’’ (1 rats died during halothane
anaesthesia and 7 rats from embolization) and 40% (8/20) in
group ‘‘stroke 8 ds’’ (2 rats died during halothane anaesthesia and
6 rats from embolization). In each group, we then selected
surviving rats from the number of microspheres found in their
brain so that the distribution of stroke severity was large but
similar among groups. Accordingly, a certain number of rats were
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selected, and the number of microspheres expressed as mean 6
SD (minimal-maximal value) was 476683 (328–615) in the ‘‘stroke
4 h’’ group, 4126122 (288–618) in the ‘‘stroke 24 h’’ group,
413697 (271–554) in the ‘‘stroke 8 d’’ group, and 368682 (242–
487 for range) in the ‘‘stroke 8 ds’’ group. It was not surprising that
the highest degree of cerebral embolization was lower in the
groups ‘‘stroke 8 d’’(554) and ‘‘stroke 8 ds’’ (487) than in groups
‘‘stroke 4 h’’ (615) and ‘‘stroke 24 h’’ (618) since highly embolized
rats did not generally survive beyond 24 h. However, the
distribution of stroke severity was large and quite similar in
groups ‘‘stroke 4 h’’, ‘‘stroke 24’’ and ‘‘stroke 8 d’’. Brain BDNF
levels measured in selected embolized rats were compared to those
measured in control rats (no surgical procedure but anaesthesia
and blood collection were on the model of group ‘‘stroke 8 d’’,
n=7).
1) Regional distribution of BDNF in the brain
The regional distribution of BDNF was investigated in intact
rats (no surgical procedure and no blood collection, n=7). The
results showed that the hippocampus contained the highest levels
of BDNF (6.9460.88 mg/mg) followed by the thalamus
(5.3261.19 mg/mg), the striatum (3.5960.39 mg/mg) and the
cortex (3.2160.26 mg/mg). However, after consideration of the
difference in fresh weight (mg) between the structures (6865 for
the hippocampus, 8369 for the thalamus, 5966 for the striatum
and 402622 for the cortex), it appeared that 50% of the total
amount of BDNF found in the brain is cortical, the remaining
BDNF being distributed in equivalent part between the hippo-
campus and other regions (thalamus and striatum).
2) Effect of stroke on circulating BDNF levels
The effect of stroke on circulating BDNF levels was assessed
from the serial measurement of serum and plasma levels in the
groups ‘‘stroke 8 ds’’ (Figure 1) and ‘‘stroke 8 d’’ (Figure 2),
respectively. In these two groups, the distribution of stroke severity
was quite similar (please compare individual degree of emboliza-
tion between Figure 1 and Figure 2). Stroke did not modify serum
BDNF levels (Figure 1A), and individual serum BDNF levels did
not correlate with stroke severity at any time point after stroke
(Figure 1B). Like serum levels, pre- and post-embolization plasma
BDNF levels were not significantly different (Figure 2A). However,
a positive correlation was observed between plasma BDNF levels
at 4 h post-embolization and stroke severity (n=10, rs=0.673,
p=0.019) (Figure 2B). At other time points, no association was
observed between the two parameters. The stroke severity-
dependant changes in plasma BDNF levels at 4 h post-emboliza-
tion coincided with the great inter-individual variability in plasma
BDNF levels observed at this time point (please compare the
standard deviation obtained at 4 h, 24 h and 8 d post-emboliza-
tion in Figure 2A). Notably, a positive correlation between plasma
BDNF levels at 4 h post-embolization and the degree of
embolization was also found after pooling the groups ‘‘stroke
4 h’’, stroke 24 h’’ and stroke 8 d’’ (n=30, rs=0.364, p=0.024).
In these rats, pre- and 4 h post-embolization plasma BDNF levels
were again not statistically different (22.2616.5 and
37.8644.6 ng/mL before and 4 h after embolization, n=30, NS).
3) Relationship between brain and circulating BDNF after
stroke
Figure 3A showed brain BDNF levels in intact and embolized
rats (groups ‘‘stroke 4 h’’, ‘‘stroke 24 h’’, and ‘‘stroke 8 d’’). Stroke
significantly (Figure 3A) increased brain BDNF levels at 4 h and
24 h post-embolization, but the levels did not correlate with the
degree of embolization in any of the three time groups of stroke
rats (Figure 3B). When plasma BDNF levels were plotted against
brain BDNF levels measured at the same time (4 h, 24 h or 8 d)
after stroke we did not find any correlation between the two
parameters (Figure 4).
As expected, no difference in brain BDNF levels (ng/g) was
observed between groups ‘‘stroke 8 d’’ (3.7460.22) and ‘‘stroke
8d s’’ (3.3660.68). When serum BDNF levels were plotted against
brain BDNF levels, both parameters being measured at day 8 post-
embolization, we did not find any correlation between the two
parameters (n=10, rs=0.139, NS, data not shown).
Discussion
BDNF levels were measured in the whole brain and in the blood
(plasma and serum) collected from the jugular vein in rats
subjected to different severities of unilateral embolic stroke. Global
rather than local brain BDNF levels were measured because the
brain has been proposed to be a potential source of BDNF present
in the blood. The measurements were made before stroke and up
to 8 d after stroke. The results report an increase in brain BDNF
levels at 4 and 24 h after stroke onset, which, however, was not
accompanied by parallel changes in plasma or serum.
In the present study, embolic stroke was induced by the
injection into the left carotid circulation of 50 mm-calibrated
microspheres, a model that results in severe ischemia of the left
hemisphere and formation of multiple infarcts that primarily
Figure 1. Serum BDNF after stroke. A) BDNF levels were serially measured before and 4 h, 24 h, 8 d after embolization in the ‘‘stroke 8 ds’’ group
(n=10), B) Scatter plot between individual BDNF levels and degree of cerebral embolization according to the time of measurement of BDNF levels
after embolization. Data are expressed as mean 6 SD, BE=before embolization, rs=Spearman’s rank correlation coefficient.
doi:10.1371/journal.pone.0029405.g001
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thalamostriate areas [21,22]. This model is unique because it
allows inducing a large but controlled distribution of degrees of
stroke severity by changing the number of injected microspheres.
The present results showed that brain BDNF content increased
after embolization and that the increase was not correlated with
the degree of embolization. The lack of correlation between the
two parameters supports our previous study revealing that the
induction of BDNF synthesis in non-neuronal cells and BDNF
over-expression by surviving neurons compensate for neuronal
death-induced decreases in brain BDNF synthesis [13].
In stroke patients, circulating BDNF levels before hospital
admission are unknown. Therefore, the effect of stroke on
circulating BDNF can only be assessed by comparing BDNF
levels in stroke patients with those in healthy subjects. However,
difference between the two populations in life style, living
environment and indices of metabolic and cardiovascular health,
which are determinants of both plasma and serum BDNF levels
[26,27] may be confounding factors. Our present animal study in
which BDNF levels were measured before and after embolization
in the same rats offers the unique opportunity to directly
investigate the effect of stroke on circulating BDNF levels. Our
results revealed that stroke did not significantly change plasma
BDNF levels when stroke severity was not taken into account. In
contrast, a positive correlation was observed between plasma
BDNF levels and stroke severity in the acute stage of stroke (4 h
post-embolization). At the first sight, these data contrast with a
study conducted on a small cohort (n=10) of stroke patients [16].
This study reported a remarkable stability in plasma BDNF levels
from hospital admission up to 4 d as well as a lack of correlation
between plasma BDNF levels and the lesion size or the clinical
score. However, it is possible that the first blood sample was
collected too late in stroke patients (10.7 h67.6 for SD vs 4 h post-
embolization), thus missing the opportunity to detect stroke
severity-dependent changes in plasma BDNF levels in patients.
Alternatively, the lack of correlation may be due to a small number
of patients with severe stroke (only two patients with a NIHSS
.16, data on lesion size were not available). The mechanisms by
which plasma BDNF levels at 4 h post-embolization are related to
stroke severity have not been investigated here. However, the fact
that plasma but not brain BDNF correlated with stroke severity
supports the hypothesis that the excess of BDNF found in plasma
of rats with severe stroke do not originate from the brain. An
alternative but still speculative source of BDNF could be the
endothelium. Indeed, circulating levels of pro-inflammatory
cytokines or markers of oxidative stress at hospital admission have
been previously correlated with stroke severity [28,29]. Beside,
when exposed to oxidative stress and pro-inflammatory cytokines
endothelial cells synthesize and secrete high amounts of BDNF
[3,5]. Notably, cerebral endothelial cells express BDNF after brain
embolization [13], and endothelium from the heart and the aorta
shows strong basal BDNF immunoreactivity in rats (unpublished
results of our laboratory). Whereas plasma BDNF is taken up by
platelets, the elevation of plasma BDNF levels at 4 h post-
Figure 2. Plasma BDNF levels after stroke. A) BDNF levels were serially measured before and 4 h, 24 h, 8 d after embolization in the ‘‘stroke 8 d’’
group (n=10), B) Scatter plot between individual BDNF levels and degree of cerebral embolization according to the time of measurement of BDNF
levels after embolization. Data are expressed as mean 6 SD, BE=before embolization, rs=Spearman’s rank correlation coefficient.
doi:10.1371/journal.pone.0029405.g002
Figure 3. Brain BDNF levels after stroke. A) brain was collected in control rats (empty bars, 7 rats) and in the ‘‘stroke 4 h’’, ‘‘stroke 24 h’’, and
‘‘stroke 8 d’’ groups (dashed bars, 10 rats per group), B). Scatter plot between levels of BDNF in individual brains and degree of cerebral embolization.
Data are expressed as mean 6 SD, * significantly different from control rats (p,0.016), rs=Spearman’s rank correlation coefficient.
doi:10.1371/journal.pone.0029405.g003
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as evidenced by the lack of change of BDNF levels in serum after
stroke. As BDNF levels are 200 times higher in serum than in
plasma (in rats and humans), we suggest that severe stroke-induced
elevation in plasma BDNF levels is too low to induce detectable
changes in serum. Notably, it has been shown that serum BDNF
levels were not associated with lesion size or recovery in stroke
patients [17,18]. Further clinical studies are needed to evaluate the
reliability of plasma BDNF as an early biological marker of stroke
severity.
The interpretation of circulating BDNF level in stroke patients
has been made on the basis of the assumptions that circulating
BDNF levels mirror brain BDNF levels. Our study that is the first
to simultaneously measure circulating and brain BDNF levels in
stroke rats reveal that changes in brain BDNF levels induced by
stroke were not associated with parallel changes in plasma or
serum. Thus, whereas stroke increased brain BDNF levels at 4 h
and 24 h, it did not induce significant changes in plasma or serum.
In addition, no correlation was observed between individual
circulating and brain BDNF levels. These data clearly indicate that
circulating BDNF levels do not mirror brain levels after stroke
regardless the delay after stroke onset, thus challenging the idea
that the measurement of circulating BDNF is a reliable way to
assess BDNF levels in brain of stroke patients. The corollary is that
that only post-mortem analysis of the ischemic brain will
document the effect of human stroke on brain BDNF levels.
Assuming that circulating BDNF levels do not reflect levels present
in the brain after stroke, some clinical data may need to be
reinterpreted. For instance, the stability in plasma BDNF levels
observed in stroke patients [16] remain compatible with increased
BDNF levels in the ischemic brain, and differences in serum
BDNF levels that have been reported between patients without
post-stroke depression (PSD) and PSD patients [18,19] do not
necessarily indicate that increased BDNF production in the brain
of PSD patients is compromised.
A limitation of the present study is that the stroke model used
lacks reperfusion after the initial blockage whereas reperfusion
either spontaneous or induced occurs for a certain number of
stroke patients. Therefore, our conclusion that circulating BDNF
levels do not reflect brain BDNF levels in stroke patients could
only concern patients lacking reperfusion. Nevertheless, even if
reperfusion may be associated to the passage of BDNF from the
brain into the blood, the detection in the blood of BDNF
originating from the brain appears challenging because of a
dilution effect of BDNF levels in the blood. Notably, a passage of
BDNF from the brain to the blood is possible after embolization
despite the lack of reperfusion as embolization is associated with
both a disruption of the blood-brain barrier and a residual blood
flow [20,22].
In conclusion, stroke increases BDNF levels in the whole brain
but not in the blood, and high plasma BDNF levels in the very
acute stage are associated with severe stroke.
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